The company is moving forward in working with early adopters in a limited setting of lung cancer testing, but still plans to expand its test to other cancers soon.
The partnership is part of a broader agreement between Genome BC and Genomics England to share data and tools around cancer and rare and infectious diseases.
The researchers designed a synthetic DNA method to be used as internal controls for NGS assays that could be applied to oncology, metagenomics, and immunology.
The European Molecular Genetics Quality Network, a provider of proficiency testing services for clinical genetics and molecular pathology labs, and its UK partner have been developing a new assessment scheme for NGS labs.
The company presented its findings last week at the 2016 Gastrointestinal Cancer Symposium and is preparing to launch the assay in the US later this year.
Novacyt will validate its Novaprep liquid-based cytology platform with Abbott's RealTime High Risk human papillomavirus assay.
The International Thyroid Congress and Annual Meeting of the American Thyroid Association announced studies validating diagnostics tests for several companies.
The company demonstrated high analytical sensitivity and specificity, and also showed clinical data supporting a high concordance with tumor tissue sequencing.
The partners will run several studies to validate the use of the MyPRS test in informing disease management in patients with multiple myeloma and its precursors.
In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.
Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.
In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.
Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.